About METLiT
Where MRS physics meets clinical AI.
Founded by the researchers whose work defined modern MRS AI quantification — to close the gap between decades of science and real-world clinical practice.
Scientific Foundation
Built on the world’s most cited research in MRS AI.
ISMRM Summa Cum Laude & Scientific Highlight
Awarded the highest scientific honor at ISMRM (8,000+ attendees) and selected for the Plenary Scientific Highlights session — presented to the entire conference as one of the year’s most impactful discoveries.
Invited Talks at ISMRM, OHBM & Beyond
Invited presentations and panel discussions at the world’s leading neuroimaging forums — including ISMRM and the Organization for Human Brain Mapping (OHBM).
3 Core Papers in Magnetic Resonance in Medicine
A trilogy in MRS’s premier journal (2019, 2020, 2022): from CNN-based quantification to targeted metabolite isolation to Bayesian uncertainty estimation via Monte Carlo dropout.
13+ Publications Across Neurology & Oncology
Brain, liver, and prostate MRS. Alzheimer’s, Parkinson’s, post-COVID neurochemistry, brain tumor hemorrhage, and hepatocellular carcinoma. Published in MRM, Journal of Magnetic Resonance, and more.
Intellectual Property
Global Patent Portfolio
Two patent families covering core AI quantification and spectral preprocessing technology — registered across three major jurisdictions.
AI-based Metabolite Quantification
Apparatus and method for non-invasive in-vivo metabolite quantification using artificial neural networks.
Spectral Preprocessing Engine
Preprocessing apparatus for non-invasive in-vivo metabolite quantification using artificial neural networks.
Our Journey
From research breakthrough to global clinical validation.
Academic Foundation
First publication on MRS baseline parameterization at Seoul National University. Laying the signal processing groundwork for what would become METLiT.
Global Recognition
ISMRM Summa Cum Laude Award. First foundational paper published in Magnetic Resonance in Medicine — CNN-based intact metabolite spectrum mining.
Uncertainty Quantification
Second core paper: deep learning-based target metabolite isolation with big data-driven measurement uncertainty estimation.
Company Founded
METLiT incorporated. Seed investment secured. Domain experts transition from academia to build a clinical-grade platform.
Bayesian Deep Learning
Third core paper: Bayesian CNN with Monte Carlo dropout for metabolite quantification with uncertainty estimation. Core engine architecture finalized.
Clinical Platform
Transition from research tool to integrated AI-native clinical system with agentic processing pipeline.
Global Validation & IP
Multi-vendor scanner validation completed. 2 patent families secured across Korea, EU, and Japan. International clinical partnerships established.
International Clinical Studies
Multi-center clinical studies across three continents. Major presentations at ISMRM annual meeting. Publications expanding into liver and prostate MRS.
Clinical Deployment
Medical device regulatory submissions and global commercial deployment in progress.
Advancing MRI with Molecular Insights.
Whether you're a clinician, researcher, or institution — let's explore what MRS can do for your patients.